Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03215719 · ClinicalTrials.gov registry record · Phase 2
Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma
A Phase 2 study of HPV Positive Oropharyngeal Squamous Cell Carcinoma and Oropharyngeal Carcinoma, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT03215719 is a Phase 2 study of HPV Positive Oropharyngeal Squamous Cell Carcinoma and Oropharyngeal Carcinoma that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 120 participants, above the 84-participant average among 16 other HPV Positive Oropharyngeal Squamous Cell Carcinoma trials with a reported enrollment target (43% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03215719, a Phase 2 study of HPV Positive Oropharyngeal Squamous Cell Carcinoma and Oropharyngeal Carcinoma, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase II clinical trial. The purpose of this study is to determine the feasibility of deescalating chemoradiation treatment based on mid-treatment tumor response determined by rapid nodal shrinkage and clearance of circulating HPV plasma tumor DNA . The primary objective of this study is to evaluate progression-free survival at 2 years.
Conditions Studied
Interventions
- RADIATION Standard Radiation Treatment
- RADIATION Dose-Deescalated Treatment
- DRUG Cisplatinum
Study Locations (1)
New York
- New York University School of Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2017-10-18 |
| Est. Completion | 2028-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03215719
The ClinicalTrials.gov registry entry for NCT03215719 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 84-participant average among 16 other HPV Positive Oropharyngeal Squamous Cell Carcinoma trials with a reported enrollment target (43% higher). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with HPV Positive Oropharyngeal Squamous Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Standard Radiation Treatment is the first listed.
NCT03215719 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03215719 about?
NCT03215719 is a clinical study titled "Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma". This is a phase II clinical trial. The purpose of this study is to determine the feasibility of deescalating chemoradiation treatment based on mid-treatment tumor response determined by rapid nodal shrinkage and clearance of circulating HPV plasma tumor DNA . The primary objective of this study is t...
What is the current status of trial NCT03215719?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2017-10-18. Estimated completion is 2028-12.
What conditions does trial NCT03215719 study?
This clinical trial studies the following conditions: HPV Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Carcinoma.
What interventions are being tested in trial NCT03215719?
The interventions under investigation include: Standard Radiation Treatment (RADIATION), Dose-Deescalated Treatment (RADIATION), Cisplatinum (DRUG).
Who is sponsoring clinical trial NCT03215719?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03215719 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HPV Positive Oropharyngeal Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)
RECRUITING · Phase 2
-
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
RECRUITING · Phase 2
-
Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer
RECRUITING · Phase 2
-
Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study
RECRUITING · Phase 2
-
The Sinai Robotic Surgery Trial in HPV-related Oropharyngeal Squamous Cell Carcinoma (SIRS 2.0 Trial)
RECRUITING · Phase 2
-
Trial of De-Intensified Post-operative Chemoradiation Following Robotic Surgery for HPV-positive Oropharyngeal Cancer
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
HPV Positive Oropharyngeal Squamous Cell Carcinoma
All registered trials for this condition
Oropharyngeal Carcinoma
All registered trials for this condition
New York
All trials with a study site in New York
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.